Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease | Zendy

Ian Pavord | Zendy; Pascal Chanez | Zendy; Gerard J. Criner | Zendy; Huib A.M. Kerstjens | Zendy; Stephanie Korn | Zendy; Njira Lugogo | Zendy; JeanBenoît Martinot | Zendy; Hironori Sagara | Zendy; Frank C. Albers | Zendy; Eric Bradford | Zendy; Stephanie Harris | Zendy; Bhabita Mayer | Zendy; David Rubin | Zendy; Steven W. Yancey | Zendy; Frank C. Sciurba | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

Author(s) -

Ian Pavord,

Pascal Chanez,

Gerard J. Criner,

Huib A.M. Kerstjens,

Stephanie Korn,

Njira Lugogo,

JeanBenoît Martinot,

Hironori Sagara,

Frank C. Albers,

Eric Bradford,

Stephanie Harris,

Bhabita Mayer,

David Rubin,

Steven W. Yancey,

Frank C. Sciurba

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1708208

Subject(s) - mepolizumab , medicine , population , copd , placebo , gastroenterology , confidence interval , clinical endpoint , eosinophil , randomized controlled trial , asthma , pathology , alternative medicine , environmental health

Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research